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Background. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1060 study demon-
strated short-term superiority of lopinavir/ritonavir (LPV/r) over nevirapine (NVP) in antiretroviral therapy (ART), regardless of
prior NVP exposure. However, NVP-based ART had a marginal benefit in CD4 percentage (CD4%) and growth. We compared
5-year outcomes from this clinical trial.
Methods. Human immunodeficiency virus (HIV)–infected, ART-eligible children were enrolled into 2 cohorts based on prior
NVP exposure and randomized to NVP- or LPV/r-based ART. The data safety monitoring board recommended unblinding results
in both cohorts due to superiority of LPV/r for the primary endpoint: stopping randomized treatment, virologic failure (VF), or death
by 6 months. Participants were offered a switch in regimens (if on NVP) and continued observational follow-up. We compared time
to VF or death, death, and CD4% and growth changes using intention-to-treat analyses. Additionally, inverse probability weights
were used to account for treatment switching and censoring.
Results. As of September 2014, 329 of the 451 (73%) enrolled participants were still in follow-up (median, 5.3 years; interquartile
range [IQR], 4.3–6.4), with 52% on NVP and 88% on LPV/r as originally randomized. NVP arm participants had significantly higher
risk of VF or death (adjusted hazard ratio [aHR], 1.90; 95% confidence interval [CI], 1.37–2.65) but not death alone (aHR, 1.65; 95%
CI, .72–3.76) compared with participants randomized to LPV/r. Mean CD4% was significantly higher in the NVP arm up to 1 year
after ART initiation, but not beyond. Mean weight-for-age z scores were marginally higher in the NVP arm, but height-for-age z
scores did not differ. Similar trends were observed in sensitivity analyses.
Conclusions. These findings support the current World Health Organization recommendation of LPV/r in first-line ART reg-
imens for HIV-infected children.
Clinical Trials Registration. NCT00307151.
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Without intervention, more than half of human immunodefi-
ciency virus (HIV)–infected children in resource-limited coun-
tries experience rapid disease progression and die by 2 years of
age [1]. Early initiation of antiretroviral therapy (ART) in chil-
dren reduces the risk of severe morbidity and mortality by 75%
[2]. The World Health Organization (WHO) currently recom-
mends universal ART for all HIV-infected individuals, including
children <10 years of age, regardless of immunologic status [3].
Fully implemented, this simplified treatment approach will in-
crease coverage in settings where pediatric HIV burden is highest.
Key advances in clinical research, policy, and implementation
have fueled efforts toward prevention of mother-to-child HIV
transmission (PMTCT) globally [4].New pediatric HIV infections
have declined dramatically; however, children who acquire HIV
often do sowhile exposed to antiretroviral drugs. The development
of antiretroviral drug resistance with failed PMTCT is well docu-
mented in the setting of “single-dose” nevirapine (NVP) for
PMTCT [5–7]; however, similar complications may occur with
continuous infant nevirapine prophylaxis or maternal ART [8–
10].Ongoing work is needed to optimize pediatric ART, to ensure
that the regimens offered are effective and durable over time.
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The International Maternal Pediatric Adolescent AIDS Clinical
Trials Network (IMPAACT) P1060 trial was designed to assess the
safety and efficacy of 2 ART regimens for children <3 years of age
with and without prior exposure to single-dose NVP for PMTCT.
By 12 months, the lopinavir/ritonavir (LPV/r)–based regimen was
associated with fewer virologic treatment failures or deaths com-
pared with the NVP-based regimen. However, improvements in
CD4 percentage (CD4%) and growth (weight-for-age and
height-for-age z score) marginally favored NVP [11, 12]. To better
understand the comparative long-term effect of these 2 ART reg-
imens in an HIV-infected pediatric population, we present data
from extended follow-up in this multicenter clinical trial.
METHODS
Study Design
IMPAACT P1060 comprised 2 parallel, randomized trials tar-
geting children with and without documented exposure to peri-
partum single-dose NVP. A full description of study procedures
is published elsewhere [11, 12]. In brief, infants and young chil-
dren aged 2 months to 3 years were recruited once ART eligibil-
ity was established. Participants were randomized to receive
either LPV/r- or NVP-based regimens, which included a nucle-
oside reverse transcriptase inhibitor backbone of zidovudine
and lamivudine. Children were prescribed liquid formulations
in the randomized trial; however, in the observational phase
of the study (see below), solid formulations were permitted.
The primary study endpoint was stopping randomized treat-
ment, virologic failure (VF), or death by 6 months. Participants
were considered to be off randomized treatment if they initiated
tuberculosis treatment or met protocol-defined toxicity end-
points requiring regimen discontinuation. Virologic failure
was defined as a confirmed plasma HIV type 1 (HIV-1) RNA
level <1 log10 copies/mL below the study entry level at 4–6
months after starting treatment, a confirmed HIV-1 RNA
level >400 copies/mL at 6 months, or 2 consecutive HIV-1
RNA levels >4000 copies/mL after 6 months. The planned sam-
ple size of 288 participants in each of the 2 cohorts, or 576 over-
all, provided >90% power to detect an absolute difference of
20% in the rate of the primary endpoint between treatment
groups. The study opened to accrual in November 2006 and
by March 2010 had enrolled 452 children at 9 sites in Africa
(4 in South Africa and 1 each in Zimbabwe, Zambia, Malawi,
Uganda, and Tanzania) and 1 site in India.
Study History
In April 2009, the data safety monitoring board (DSMB) closed
accrual in the NVP-exposed cohort due to superiority of the
LPV/r -based treatment for the primary study endpoint [11],
but allowed the NVP-unexposed cohort to continue enrolling.
In October 2010 the DSMB recommended results be released in
the NVP-unexposed cohort, which also showed that LPV/
r-based ART was superior to the NVP treatment arm for the
primary study endpoint [12]. With closure of each cohort,
clinicians and caregivers had the choice to switch from NVP-
based ART to LPV/r-based ART. Children in both cohorts con-
tinued study follow-up every 3 months; however, site clinicians
directed HIV management based on local standards of care.
The observational follow-up study was implemented in a re-
vised protocol in March 2011, when participants were offered
continued follow-up. Parents/caregivers provided informed
consent with the child’s assent where appropriate. ART was
provided through local or national HIV programs, and drug se-
lection and toxicity management were performed according to
local standard of care. Plasma HIV-1 RNA and immunologic
and anthropometric assessments were conducted every 3
months. Figure 1 presents a CONSORT (Consolidated Stan-
dards of Reporting Trials) flow diagram summarizing the histo-
ry of the study. Data up to 21 September 2014 were included in
this analysis, as this was the last date when all sites contributed
to long-term study follow-up.
Statistical Methods
Participant follow-up spanned periods when patient manage-
ment was guided by the protocol (randomized clinical trial pe-
riod) and, following 2 separate DSMB interventions, guided by
clinician discretion (observational period). Reasons for discon-
tinuing NVP and LPV/r-based ART thus included protocol-
and non-protocol-mandated factors, which complicated the
interpretation of longer-term outcomes. To address this issue,
we considered participants to be “off study treatment” if they
discontinued their originally allocated LPV/r or NVP for at
least 30 days. In our primary analysis, we incorporated an inten-
tion-to-treat (ITT) approach. To evaluate whether differential
treatment switching and censoring were influencing conclu-
sions, we performed sensitivity analyses using inverse probabil-
ity weighting [13–15]. Details of methods for the weighted
models are given in the Supplementary Appendix. We pooled
data from both cohorts, following analyses demonstrating that
previous NVP exposure was not associated with differential
treatment outcomes between the 2 randomization arms [16].
Kaplan–Meier curves were used to illustrate time to VF or
death (VF/death) and death alone. Mean (95% confidence in-
terval [CI]) CD4%, WHO weight-for-age z (WAZ) scores,
and WHO height-for-age z (HAZ) scores were summarized at
targeted times (entry, 6 months, and then every 12 months)
[17]. Cox proportional hazards models were used to analyze
time-to-event outcomes, and generalized estimating equations
were used to fit models to compare CD4% and growth out-
comes in children on the 2 treatment regimens. Adjusted mod-
els included sex, prior NVP exposure (cohort), age at entry (<1
years; ≥1 year), HIV-1 RNA (<750 000; ≥750 000 copies/mL),
CD4% (<15%; 15% to <25%; ≥25%), HAZ score and WAZ
score (by tertile of all values at entry), and WHO stage
(I/II; III/IV). Two-sided P values unadjusted for multiple
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comparisons were reported. Analyses were conducted using
SAS 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
Baseline and Current Characteristics
Overall, 452 infants and children were randomized between
November 2006 and March 2010; 451 started treatment and
were included in the analyses (229 in the NVP arm and 222
in the LPV/r arm). At enrollment, 44% of participants were
<12 months of age. Most children had relatively advanced dis-
ease: baseline median CD4% 16% and plasma HIV-1 RNA
687 000 copies/mL; 61% were WHO stage III/IV (Table 1).
As of 21 September 2014, 329 of the 451 (73%) remained
in study follow-up (Supplementary Table 1). Twenty-five
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram of participant flow through the different stages of the International Maternal Pediatric Adolescent
AIDS Clinical Trials Network P1060 trial. Abbreviations: 3TC, lamivudine; DSMB, data safety monitoring board; LPV/r, lopinavir/ritonavir; NVP, nevirapine; ZDV, zidovudine.
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participants had died (16 on NVP and 9 on LPV/r), 44 were
unable to continue with clinic visits (mostly because of relocation
outside of the study area), and 24 declined enrollment in the ob-
servational phase. Median follow-up was 5.3 years (interquartile
range [IQR], 4.3–6.4), with no differences between the 2 treat-
ment arms (5.2 years for NVP vs 5.3 years for LPV/r; P = .47).
Characteristics at the most recent clinic visit before the data cut-
off are summarized in Supplementary Table 2. Median CD4%
was 37%, and 94% had HIV-1 RNA ≤400 copies/mL.
Of participants randomized to NVP, 52% remained in follow-
up on NVP and 33% had been switched to LPV/r. Of those ran-
domized to LPV/r, 88% were in follow-up on LPV/r, and only
4% had been switched to NVP. Median time on study drug
was 20.5 months (IQR, 6.4–63.7 months) for NVP and 61.2
months (IQR, 28.1–71.9 months) for LPV/r. Time to discontin-
uation of NVP or LPV/r is shown in Supplementary Figure 1. Of
the 152 participants who stopped NVP or LPV/r, approximately
two-thirds did so for protocol-mandated reasons. Fourteen were
taken off NVP after the DSMB closure of enrollment to the
NVP-exposed cohort. Reasons for discontinuing randomized
study drugs are shown in Supplementary Table 3.
Virologic Failure and Death
An early separation by treatment arm in time to VF/death was
observed by 6 months and the curves remained separated
throughout follow-up, with relatively few events occurring
Table 1. Baseline Characteristics of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy in the International Maternal
Pediatric Adolescent AIDS Clinical Trials Network P1060 Trial, Stratified by Original Randomization Arm
Characteristic
Randomization Arm
NVP (n = 229) LPV/r (n = 222) Total (N = 451)
Prior NVP exposure
Exposed 82 (36) 82 (37) 164 (36)
Unexposed 147 (64) 140 (63) 287 (64)
Age
Median (Q1, Q3) 1.19 (0.71–2.10) 1.23 (0.65–1.97) 1.22 (0.68–2.07)
<12 mo 100 (44) 100 (45) 200 (44)
≥12 mo 129 (56) 122 (55) 251 (56)
Sex
Male 105 (46) 110 (50) 215 (48)
Female 124 (54) 112 (50) 236 (52)
CD4%
Median (Q1, Q3) 16 (12–21) 17 (12–22) 16 (12–22)
<15% 97 (43) 90 (41) 187 (42)
15% to <25% 97 (43) 91 (41) 188 (42)
≥25% 34 (15) 41 (18) 75 (17)
Missing 1 0 1
Weight-for-age z scorea
Median (Q1, Q3) −1.54 (−2.84 to −0.65) −1.59 (−2.54 to −0.62) −1.57 (−2.71 to −0.63)
<−2.22 80 (35) 68 (31) 148 (33)
−2.22 to <−1.04 73 (32) 76 (34) 149 (33)
≥−1.04 76 (33) 78 (35) 154 (34)
Height-for-age z score a
Median (Q1, Q3) −2.40 (−3.39 to −1.34) −2.17 (−3.14 to −1.14) −2.31 (−3.31 to −1.24)
<−2.97 76 (33) 69 (31) 145 (32)
−2.97 to <−1.63 81 (35) 71 (32) 152 (34)
≥−1.63 72 (31) 82 (37) 154 (34)
Clinical stage (WHO)
Stage I/II 85 (37) 92 (41) 177 (39)
Stage III/IV 144 (63) 130 (59) 274 (61)
HIV-1 RNA, copies/mLb
Median (Q1, Q3) 689 000 (250 000–750 000) 680 918 (225 034–750 000) 687 000 (232 882–750 000)
<750 000 123 (54) 119 (54) 242 (54)
≥750 000 106 (46) 103 (46) 209 (46)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: HIV-1, human immunodeficiency virus type 1; LPV/r, lopinavir/ritonavir; NVP, nevirapine; WHO, World Health Organization.
a Tertiles of entry distribution.
b Censored at 400 copies/mL and 750 000 copies/mL.
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beyond 24 months. The proportion of participants experiencing
VF/death by 6 months in the NVP arm was 17% greater than in
the LPV/r arm (P < .001) (Figure 2). This difference persisted at
12 months (17%; P < .001), 36 months (19%; P < .001), and 60
months (19%; P < .001). The hazard ratio (HR) for VF/death
was significantly higher among children initiating NVP com-
pared with LPV/r, both in crude (HR, 1.87; 95% CI, 1.35–2.61)
and multivariable (adjusted HR, 1.90; 95% CI, 1.37–2.65) Cox
regression models. Results from the sensitivity analysis gave an
estimated rate ratio of 2.90 (95% CI, 1.67–5.06) when compared
to LPV/r. Time to VF/death by treatment arm and entry HIV-1
RNA level is illustrated in Figure 2, showing that differences in
outcomes varied little by initial viral loads. Time to VF/death
by treatment arm and prior NVP exposure is illustrated in
Supplementary Figure 2. Differences in outcomes varied little
regardless of NVP exposure for PMTCT.
Death was an early phenomenon, primarily in the first 3–6
months of follow-up (Figure 2). Of the 16 deaths in the NVP
arm, 14 occurred during NVP-based ART. Eight of the 9 deaths
in the LPV/r arm occurred while receiving LPV/r-based ART.
Infants and children initiating NVP were at greater risk for
death, but the difference was not statistically significant in either
unadjusted (HR, 1.78; 95% CI, .79–4.04) or adjusted Cox mod-
els (adjusted HR, 1.65; 95% CI, .72–3.76). The estimated rate
ratio from weighted models (1.95; 95% CI, .82–4.66) gave sim-
ilar findings.
CD4 Percentage Over Time
Mean CD4% over time by randomized treatment arm overall
and by entry levels is shown in Figure 3. Children with lower
initial values demonstrated greater improvement than those
with higher values at baseline. Mean CD4% levels at 60 months
Figure 2. Kaplan–Meier analysis comparing primary outcomes in the International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1060 trial, including death
only (A), virologic failure or death (B), and virologic failure or death, stratified by baseline viremia level (C). The figures included at the bottom of each graph represent the
number of participants at risk at each time point. Abbreviations: LPV/r, lopinavir/ritonavir; NVP, nevirapine.
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were >25% regardless of initial level. Differences by treatment
arm are shown in Table 2. In ITT unadjusted models, there
were no statistically significant differences by treatment arm.
In adjusted models, significantly greater CD4% gains with NVP
were observed at 6 months (+1.4%; P = .06) and 12 months
(+1.5%; P = .03), but differences were not significant beyond 12
months. Therewere no statistically significant interactions between
entry levels and randomized treatment in the CD4% outcomes.
Figure 3. Trends in specific treatment outcomes (mean, 95% confidence intervals) over time for the nevirapine (NVP) and lopinavir/ritonavir (LPV/r) arms of the International
Maternal Pediatric Adolescent AIDS Clinical Trials Network P1060 trial, CD4 percentage (A and B), height-for-age z scores (C and D), and weight-for-age z scores (E and F ). The
figures included at the bottom of each graph represent the number of participants with available data at each time point.
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Growth Over Time
Mean WAZ and HAZ scores over time by randomized treat-
ment arm overall and by entry levels are shown in Figure 3.
For both measures, mean values at 60 months in participants
with the lowest levels at study entry remained lower than
those with higher values at entry. HAZ scores continued to im-
prove throughout follow-up. Differences in these outcomes by
treatment arm are shown in Table 2. In ITT unadjusted models,
no statistically significant differences between the treatment
arms were detected at any time point except for WAZ scores
at 5 years (mean NVP z score 0.23 higher, P = .03). In adjusted
models, mean WAZ scores were marginally higher in the NVP
arm at all the time points (smallest difference: month 24 by
0.15, P = .11; largest difference: month 60 by 0.25, P = .01).
HAZ scores were marginally higher in the NVP arm only at 6
months (by 0.17, P = .08). Similar trends were observed in sen-
sitivity analyses. There were no statistically significant interac-
tions between entry levels and randomized treatment in the
growth outcomes.
DISCUSSION
In this study of HIV-infected infants with and without prior ex-
posure to NVP at birth, participants randomized to NVP-based
ART had higher risk for virologic failure or death (primary out-
come) compared with those randomized to LPV/r-based ART.
These findings, reported in early analyses [11, 12], remained
consistent over a median follow-up of >5 years. Separation of
treatment effect by arm occurred early; thereafter, children on
both treatment arms experienced relative stability. The first
4–6 months of ART appears to be an especially high-risk period
for NVP-treated infants in terms of virologic failure or death. If
successfully navigated, such infants are able to achieve and sus-
tain virologic suppression at rates similar to those of LPV/r-
treated infants.
These results differ from other large clinical trials. The PEN-
PACT 1 (PENTA 9/PACTG 390) and the Prevention of Malaria
and HIV disease in Tororo (PROMOTE) studies, for example,
did not show significant differences in treatment outcomes be-
tween protease inhibitor (PI)– and nonnucleoside reverse tran-
scriptase inhibitor (NNRTI)–based ART regimens in children
[18, 19]. However, in both studies, the median age of enrollment
was considerably older (6.5 and 3.1 years, respectively, vs 1.2
years in the current study). In addition, PI and NNRTI choices
were not limited to LPV/r and NVP alone. The Optimal Combi-
nation Therapy after Nevirapine Exposure (OCTANE) study
randomized adult women with and without prior NVP exposure
to either NVP- or LPV/r-based ART, using a design similar to IM-
PAACT P1060. In women with prior NVP exposure, LPV/r was
superior for the time to VF/death outcome [20]; among women
without prior NVP exposure, however, the 2 regimens had similar
long-term outcomes [20].Similarly, Clumeck and colleagues in the
Democratic Republic of the Congo found no differences in
Table 2. Treatment Differences in CD4 Percentage, Weight-for-age z Score, and Height-for-age z Score Outcomes Over Time, Between the Nevirapine and
Lopinavir/Ritonavir Arms of the International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1060 Trial
Outcome Time
Intention-to-Treat Unadjusted Intention-to-Treat Adjusteda
Inverse Probability Weighting
Modela
Estimate (95% CI) P Value Estimate (95% CI) P Value Estimate (95% CI) P Value
CD4% 6 mo 0.94 (−.81 to 2.69) .29 1.42 (−.06 to 2.90) .06 1.15 (−.35 to 2.65) .13
12 mo 1.23 (−.36 to 2.82) .13 1.53 (.13 to 2.93) .03 1.24 (−.17 to 2.66) .08
24 mo 0.44 (−1.17 to 2.05) .59 0.79 (−.68 to 2.26) .29 0.01 (−1.50 to 1.51) .99
36 mo 0.17 (−1.51 to 1.85) .84 0.19 (−1.39 to 1.76) .82 0.96 (−.64 to 2.56) .24
48 mo 0.01 (−1.61 to 1.62) .99 0.10 (−1.43 to 1.64) .90 0.66 (−.90 to 2.21) .41
60 mo 0.91 (−.66 to 2.48) .26 1.08 (−.41 to 2.57) .16 1.27 (−.16 to 2.70) .08
Weight-for-age z score 6 mo 0.14 (−.11 to .38) .28 0.21 (.04 to .39) .02 0.22 (.04 to .39) .01
12 mo 0.19 (−.03 to .41) .09 0.22 (.05 to .39) .01 0.20 (.02 to .37) .03
24 mo 0.14 (−.08 to .36) .20 0.15 (−.03 to .32) .11 0.12 (−.06 to .30) .21
36 mo 0.18 (−.02 to .38) .08 0.21 (.05 to .38) .01 0.26 (.10 to .43) .002
48 mo 0.16 (−.04 to .35) .12 0.16 (−.01 to .33) .06 0.27 (.09 to .45) .003
60 mo 0.23 (.02 to .43) .03 0.25 (.08 to .43) .01 0.42 (.24 to .60) <.001
Height-for-age z score 6 mo 0.04 (−.24 to .31) .80 0.17 (−.02 to .35) .08 0.17 (−.01 to .35) .07
12 mo 0.04 (−.21 to .29) .74 0.12 (−.06 to .30) .18 0.11 (−.07 to .28) .24
24 mo 0.01 (−.23 to .25) .93 0.08 (−.11 to .27) .39 0.04 (−.15 to .23) .67
36 mo 0.03 (−.20 to .27) .79 0.14 (−.04 to .33) .14 0.08 (−.10 to .26) .37
48 mo 0.02 (−.20 to .25) .83 0.08 (−.11 to .26) .41 0.12 (−.06 to .29) .19
60 mo 0.06 (−.16 to .28) .60 0.11 (−.08 to .29) .26 0.16 (−.02 to .34) .07
Differences based on values from the NVP arm minus values from the LPV/r arm.
Abbreviations: CI, confidence interval; LPV/r, lopinavir/ritonavir; NVP, nevirapine.
a Adjusted for entry randomized regimen, sex, cohort, age, human immunodeficiency virus type 1 RNA, CD4%, growth tertile, and World Health Organization stage.
HIV/AIDS • CID 2016:63 (15 October) • 1119
therapeutic failure among adults after randomization to LPV/r- or
NVP-based regimens, although overall failure rates were high (ap-
proximately 30%) [21]. The reasons for different outcomes be-
tween IMPAACT P1060 and other trials may relate to
characteristics of the study participants, who were very young
(44% under 12 years of age), with high baseline viremia (46%
with >750 000 copies/mL) and advanced clinical staging (61%
with stage III/IV). The high levels of viral replication among
newly infected infants require a longer time on ART to achieve
viral suppression. It is possible that for drugs requiring only a sin-
gle mutation to confer resistance (such as NVP), there is increased
risk for virologic failure during this window period. This was
borne out by the high rate of NNRTI resistance detected among
children failing NVP-based ART in IMPAACT P1060 [11, 12].
In addition, the ramp-up strategy commonly used at NVP initia-
tion (half-dose prescribed for an initial 2 weeks to minimize risk
for toxicity), as practiced in this study, could give suboptimal drug
levels when viral replication remains high.
Previous analyses of IMPAACT P1060 suggested better
growth and CD4% recovery among participants randomized
to NVP-based ART at 6 and 12 months [11, 12], findings con-
sistent with at least 1 other clinical trial [22]. We reexamined
this important scientific question with the longer follow-up
available in both cohorts. Differences in CD4% by treatment
arm remained marginally significant at 12 months but not be-
yond. Mean HAZ scores were also higher in the NVP arm, but
differences were not significant. Differences in WAZ scores, al-
though significantly higher in the NVP arm, were of relatively
small magnitude. For example, for a 6-year-old boy with a WAZ
score of −0.78 (median at the time of database freeze), the 0.25
difference in z scores at year 5 predicted by adjusted ITT anal-
yses translates to a weight difference of approximately 0.7 kg.
Reasons for these findings may include the poor palatability
(particularly with liquid formulations), appetite suppression,
and metabolic effects associated with LPV/r and other protease
inhibitors [23–25]. Interestingly, despite the reputation of liquid
LPV/r formulations for challenging administration, the IM-
PAACT P1060 trial demonstrated remarkable acceptability
and adherence among these young infants, with desirable
short- and long-term outcomes.
Despite our findings from IMPAACT P1060, NVP remains
an important component of a broader armamentarium for pe-
diatric ART. When LPV/r is not available, NVP-based regimens
are a viable alternative, particularly when virologic monitoring
is available. The persistent gap between adult and pediatric ac-
cess to ART has been well documented [26]. An approach that
realistically considers availability of antiretroviral drugs across
different settings is critical to reaching the millions of HIV-
infected children worldwide.
Key strengths of this study were its randomized design and
long follow-up. The combination of participant follow-up
from both the randomized and nonrandomized time periods
of the study, however, added a degree of complexity to the
analysis. While we relied on an ITT approach for the primary
analysis, we also performed sensitivity analyses to account for
treatment switching and censoring during follow-up. That the
results of the ITT analysis and the sensitivity analysis were con-
sistent was reassuring. An alternative to the composite VF or
death endpoint would have required using competing risks
methodology. For consistency with prior publications on short-
er-term outcomes, we used this protocol-defined composite
outcome. While the primary focus of this trial was HIV-related
outcomes, studies have shown unfavorable alterations in lipid
profiles and body composition among infants on LPV/r [27,
28]. Longitudinal data on such outcomes are needed as, with
current treatment recommendations, the duration of LPV/r-
based ART exposure will only increase for perinatally infected
children. Similarly, a better understanding of neurodevelopment
is needed in the context of HIV infection and specific drug reg-
imens [29].McGrath et al found that infants on NVP-based ART
demonstrated later speech attainment than those on LPV/r ART
(18.1 vs 15.5 months; P = .003), although its long-term signifi-
cance is yet unknown [30]. We are currently collecting longitudi-
nal and neuropsychological assessment data among IMPAACT
P1060 participants at several sites to address this gap. Addition-
ally, adherence to LPV/r regimens may have varied according to
the follow-up period of the study. LPV/r suspension, known for
its poor palatability, was strictly used during the randomized
study component. When the study moved into its observational
stage, local ART programs were able to provide solid-form LPV/r
to older participants.
In summary, compared with NVP-based ART, LPV/r-based
ART was associated with fewer virologic failures or deaths over
time in extended 5-year follow-up. The short-term superiority
of the NVP arm in CD4% recovery did not persist beyond 1
year, but increased weight gains with NVP remained consistent,
although minor from a clinical standpoint. These findings pro-
vide support for the continued use of LPV/r-based regimens as
part of first-line treatment for pediatric HIV.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
Notes
Acknowledgments. We thank the children, their families, and their
caregivers who agreed to participate in International Maternal Pediatric Ad-
olescent AIDS Clinical Trials Group (IMPAACT) P1060, and the site clin-
ical study teams who supported this work. We also acknowledge the
following pharmaceutical representatives and their companies for the gen-
erous provision of antiretroviral agents used in the study: Lauren Petrella
and Peter Piliero, (Boehringer-Ingelheim Pharmaceuticals), Marisol Marti-
nez (Abbott Laboratories), and Navdeep Thoofer and Wendy Snowden
(GlaxoSmithKline).
Author contributions. L. B.-M., K. A., J. L., P. P., and B. H. C. designed
the analysis, interpreted the data, and wrote the manuscript. K. A., J. L., and
1120 • CID 2016:63 (15 October) • HIV/AIDS
K. P. managed study data, conducted statistical analysis, and critically re-
vised the manuscript. M. A., M. C., S. D., L. F., E. K., P. K., A. K., T. M.,
L. M., P. S., and A. V. oversaw study activities at our recruitment sites and
critically revised the manuscript. L. B.-M., P. P., A. V., and M. A. served as
protocol co-chairs for the study and provided oversight in its design, imple-
mentation, and dissemination. L. M., P. J. P., and E. B. served on the protocol
team, assisted in data interpretation, and critically revised the manuscript.
All authors have reviewed and approved the submitted version. Members of
the writing team had full access to all the data in the study. The correspond-
ing author had final responsibility for the decision to submit for publication.
Disclaimer. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Institutes of
Health (NIH).
Financial support. This study was funded by the International Mater-
nal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), which
is supported by the National Institute of Allergy and Infectious Diseases
(NIAID) of the NIH under award numbers UM1AI068632 (IMPAACT
LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT
LC), with co-funding from the Eunice Kennedy Shriver National Institute of
Child Health and Human Development and the National Institute of Men-
tal Health. Additional salary support was provided by award number
K24AI120796 from NIAID.
Potential conflicts of interest. K. A. and J. L. report grants from the
NIH during the conduct of the study, as well as stocks and mutual funds
held broadly based on retirement funds. M. C. reports funding from the
NIH and grants from ViiV, BMS, Gilead, Novartis, VPM GmbH, and
Novavax. K. P. reports support from the NIH. P. J.-P. reports support
from the NIH through the Henry M. Jackson Foundation. A. V. reports
grants from the NIH, Columbia University School of Medicine, Gilead,
ViiV Healthcare, and Jansen Pharmaceuticals. P. P. reports personal fees
from Gilead, Merck, and ApoPharma. All other authors report no potential
conflicts. All authors have submitted the ICMJE Form for Disclosure of Po-
tential Conflicts of Interest. Conflicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortal-
ity of infected and uninfected infants born to HIV-infected mothers in Africa: a
pooled analysis. Lancet 2004; 364:1236–43.
2. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality
among HIV-infected infants. N Engl J Med 2008; 359:2233–44.
3. World Health Organization. Guideline on when to start antiretroviral therapy and
on pre-exposure prophylaxis for HIV, September 2015. Available at: http://apps.who.
int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf. Accessed 31 July 2016.
4. Chi BH, Stringer JS, Moodley D. Antiretroviral drug regimens to prevent mother-
to-child transmission of HIV: a review of scientific, program, and policy advances
for sub-Saharan Africa. Curr HIV/AIDS Rep 2013; 10:124–33.
5. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mu-
tations in women and infants receiving nevirapine to prevent HIV-1 vertical trans-
mission (HIVNET 012). AIDS 2001; 15:1951–7.
6. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance
mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose ne-
virapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126–30.
7. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women
with HIV-1 subtype C, compared with subtypes A and D, after the administration
of single-dose NVP. J Infect Dis 2005; 192:30–6.
8. Kuhn L, Hunt G, Technau KG, et al. Drug resistance among newly diagnosed
HIV-infected children in the era of more efficacious antiretroviral prophylaxis.
AIDS 2014; 28:1673–8.
9. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after
delivery can induce multiclass drug resistance in breastfeeding HIV-infected in-
fants. Clin Infect Dis 2011; 52:1069–76.
10. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breast-
feeding infants born to HIV-infected mothers during a single-arm trial of triple-
antiretroviral prophylaxis for prevention of mother-to-child transmission: a sec-
ondary analysis. PLoS Med 2011; 8:e1000430.
11. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for
children with peripartum nevirapine exposure. N Engl J Med 2010; 363:
1510–20.
12. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lo-
pinavir for HIV-infected children. N Engl J Med 2012; 366:2380–9.
13. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the
causal effect of zidovudine on the survival of HIV-positive men. Epidemiology
2000; 11:561–70.
14. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censor-
ing in an AIDS Clinical Trial with inverse probability of censoring weighted
(IPCW) log-rank tests. Biometrics 2000; 56:779–88.
15. Toh S, Hernan MA. Causal inference from longitudinal studies with baseline ran-
domization. Int J Biostat 2008; 4:22.
16. Lindsey JC, Hughes MD, Violari A, et al. Predictors of virologic and clinical
response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy
in young children with and without prior nevirapine exposure for the preven-
tion of mother-to-child HIV transmission. Pediatr Infect Dis J 2014; 33:
846–54.
17. World Health Organization Multicentre Growth Reference Study Group. WHO
child growth standards: length/height-for-age, weight-for-age, weight-for-length,
weight-for-height, and body mass index-for-age: methods and development. Ge-
neva, Switzerland: WHO Press, 2006.
18. Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antiretroviral
therapy with a protease inhibitor versus non-nucleoside reverse transcriptase in-
hibitor and switch at higher versus low viral load in HIV-infected children: an
open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11:273–83.
19. Ruel TD, Kakuru A, Ikilezi G, et al. Virologic and immunologic outcomes of HIV-
infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside re-
verse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2014;
65:535–41.
20. Paredes R, Marconi VC, Lockman S, Abrams EJ, Kuhn L. Impact of antiretroviral
drugs in pregnant women and their children in Africa: HIV resistance and treat-
ment outcomes. J Infect Dis 2013; 207(suppl 2):S93–100.
21. Clumeck N, Mwamba C, Kabeya K, et al. First-line antiretroviral therapy with ne-
virapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
AIDS 2014; 28:1143–53.
22. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-in-
fected children after protease inhibitor-based viral suppression: a randomized con-
trolled trial. JAMA 2010; 304:1082–90.
23. Nachman SA, Lindsey JC, Pelton S, et al. Growth in human immunodeficiency
virus-infected children receiving ritonavir-containing antiretroviral therapy.
Arch Pediatr Adolesc Med 2002; 156:497–503.
24. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitor-containing
combination antiretroviral therapies on height and weight growth in HIV-infected
children. Pediatrics 2001; 108:E72.
25. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic
abnormalities in vertically HIV-infected children and youth. AIDS 2009;
23:661–72.
26. Prendergast AJ, Essajee S, Penazzato M. HIV and the Millennium Development
Goals. Arch Dis Child 2015; 100(suppl 1):S48–52.
27. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected
children initiating and changing antiretroviral therapy. J Acquir Immune Defic
Syndr 2012; 60:369–76.
28. Arpadi S, Shiau S, Strehlau R, et al. Metabolic abnormalities and body composition
of HIV-infected children on lopinavir or nevirapine-based antiretroviral therapy.
Arch Dis Child 2013; 98:258–64.
29. Ngoma MS, Hunter JA, Harper JA, et al. Cognitive and language outcomes in
HIV-uninfected infants exposed to combined antiretroviral therapy in utero and
through extended breast-feeding. AIDS 2014; 28(suppl 3):S323–30.
30. McGrath CJ, Chung MH, Richardson BA, Benki-Nugent S, Warui D, John-Stewart
GC. Younger age at HAART initiation is associated with more rapid growth recon-
stitution. AIDS 2011; 25:345–55.
HIV/AIDS • CID 2016:63 (15 October) • 1121
